Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short-term intensified chemo-immunotherapy in HIV+ Burkitt lymphoma
NCT01516593Phase 2Completed
- Start
- Nov 2011
- Primary completion
- Apr 2013
- Modality
- Monoclonal Antibodies, Orthosteric Ligands, Targeted Liposomes
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab, cyclophosphamide, vincristine sulfate liposome injection, methotrexate, etoposide in Burkitt lymphoma (BL). Started Nov 2011; status: completed.
02
Drugs
rituximabcyclophosphamidevincristine sulfate liposome injectionmethotrexateetoposide
03
Conditions
Burkitt lymphoma (BL)
Beyond the preview
Go deeper on NCT01516593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01516593.